Arca
Skip to content
Tools
Tools

IL5: Interleukin-5

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Homodimeric cytokine expressed predominantly by T-lymphocytes and NK cells that plays an important role in the survival, differentiation, and chemotaxis of eosinophils.

  • Drugs that act on it: 3
  • Approved: 2
  • In phases 1 to 3: 1
  • Sponsors: 2

Who Is On It, and How Far Along

Every drug ChEMBL records acting on IL5, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody

Approved2

  • Mepolizumab
  • Reslizumab

Phase 31

  • Depemokimab

Phase 20

    Phase 10

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Interleukin-5 inhibitor.
      MepolizumabApprovedGSKAntibodyInhibitor—35—
      ReslizumabApprovedTeva Pharmaceutical IndustriesAntibodyInhibitor—3Boxed warning
      DepemokimabPhase 3GSKAntibodyInhibitor—11—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 17 in all, from ClinicalTrials.gov.
      Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic AsthmaDepemokimabNot applicableNot yet recruitingQianfoshan Hospital2026-09-18
      T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPDDepemokimab, Mepolizumab—RecruitingShanghai Pulmonary Hospital, Shanghai, China2026-09-16
      Benralizumab Effectiveness in EGPAMepolizumab—RecruitingEuropean EGPA Study Group2026-09-11
      Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS).MepolizumabPhase 4RecruitingInstituto de Investigación Marqués de Valdecilla2026-09-11
      Expression of TSLP Isoforms in AsthmaMepolizumab, Reslizumab—RecruitingMedical University of Warsaw2026-08-26
      Airway Dysfunction, Occlusions and Remodeling: COPD Patients and MepolizumabMepolizumabPhase 4Not yet recruitingWestern University, Canada2026-08-06
      Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)DepemokimabPhase 4RecruitingGlaxoSmithKline2026-07-14
      A Study of Depemokimab in Participants of 6 to 11 Years of AgeDepemokimabPhase 3RecruitingGlaxoSmithKline2026-06-26
      Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eosinophilic ACOS With BiologicsMepolizumab—Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology2026-05-22
      A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 AsthmaDepemokimabPhase 3RecruitingGlaxoSmithKline2026-03-06
      Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPAMepolizumabPhase 4Enrolling by invitationAzienda Ospedaliero Universitaria di Cagliari2026-01-15
      Complete Remission After Treatment With Biologics for Nasal PolypsMepolizumabPhase 4RecruitingCopenhagen University Hospital, Rigshospitalet2025-12-05
      eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationDepemokimabPhase 3RecruitingGlaxoSmithKline2025-09-17
      Depemokimab Asthma Imaging and Bronchoscopy Sub-StudyDepemokimabPhase 3RecruitingGlaxoSmithKline2025-05-18
      Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)DepemokimabPhase 3RecruitingGlaxoSmithKline2025-05-07
      Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic AgentsReslizumabPhase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)2024-06-27
      Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) StudyReslizumabPhase 2RecruitingNational Jewish Health2016-10-28

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Asthma
      0.73
      Chronic rhinosinusitis
      0.47
      Airway obstruction
      0.47
      Nasal cavity polyp
      0.46
      Chronic rhinosinusitis with nasal polyps
      0.41
      Childhood onset asthma
      0.38
      Atopic eczema
      0.38
      Eosinophilic granulomatosis with polyangiitis
      0.37

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1169600, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P05113, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.